ALLO Key Statistics, Chart & Performance
The current stock price of ALLO is 1.43 USD. In the past month the price increased by 36.19%. In the past year, price decreased by -34.7%.
ALLO Latest News, Press Relases and Analysis
ALLO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About ALLO
Company Profile
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 226 full-time employees. The company went IPO on 2018-10-11. The firm is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The company is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). The company is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Company Info
ALLOGENE THERAPEUTICS INC
210 East Grand Avenue
South San Francisco CALIFORNIA 94080 US
CEO: David Chang
Employees: 226
Phone: 16504572700
ALLOGENE THERAPEUTICS INC / ALLO FAQ
What does ALLO do?
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 226 full-time employees. The company went IPO on 2018-10-11. The firm is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The company is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). The company is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
What is the current price of ALLO stock?
The current stock price of ALLO is 1.43 USD. The price decreased by -0.69% in the last trading session.
Does ALLO stock pay dividends?
ALLO does not pay a dividend.
What is the ChartMill rating of ALLOGENE THERAPEUTICS INC stock?
ALLO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists ALLO stock?
ALLO stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of ALLOGENE THERAPEUTICS INC (ALLO)?
ALLOGENE THERAPEUTICS INC (ALLO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.98).
ALLO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ALLO. When comparing the yearly performance of all stocks, ALLO is a bad performer in the overall market: 68.95% of all stocks are doing better.
ALLO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALLO. ALLO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALLO Financial Highlights
Over the last trailing twelve months ALLO reported a non-GAAP Earnings per Share(EPS) of -0.98. The EPS increased by 33.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.21% | ||
| ROE | -67.24% | ||
| Debt/Equity | 0 |
ALLO Forecast & Estimates
20 analysts have analysed ALLO and the average price target is 7.71 USD. This implies a price increase of 439.24% is expected in the next year compared to the current price of 1.43.
For the next year, analysts expect an EPS growth of 24.3% and a revenue growth -83.3% for ALLO